National guidelines recommend Lp(a) testing among patients with FHx of CVD (15, 16); also, according to the dyslipidemia guidelines issued by the European Society of Cardiology/European Atherosclerosis Society in 2019, it is recommended to contemplate the assessment of Lp(a) levels in individuals with moderate and high ASCVD risk (15). This evidence concerns the gene LPA and metabolic syndrome.